SHP-2 tyrosine phosphatase is highly expressed in hematopoietic cells; however, the function of SHP-2 in hematopoietic cell processes is not fully understood. Recent identification of SHP-2 mutations in childhood leukemia further emphasizes the importance of SHP-2 regulation in hematopoietic cells. We previously reported that SHP-2 played a positive role in IL-3-induced activation of Jak2 kinase in a catalytic-dependent manner. Interestingly, enforced expression of wild-type (WT) SHP-2 in Ba/F3 cells enhanced growth factor deprivation-induced apoptosis. Biochemical analyses revealed that although IL-3 activation of Jak2 kinase was increased, tyrosyl phosphorylation of its downstream substrate STAT5 was disproportionately decreased by the overexpression of SHP-2. Following IL-3 deprivation, the tyrosyl phosphorylation of STAT5 that is required for its antiapoptotic activity was rapidly diminished in SHP-2 overexpressing cells. As a result, reduction of the putative downstream targets of STAT5-Bcl-X L and pim-1 was accelerated by overexpression of SHP-2. Further investigation showed that SHP-2 associated with STAT5, and that it was indeed able to dephosphorylate STAT5. Finally, overexpression of SHP-2 in primary bone marrow hematopoietic progenitor cells compromised their differentiative and proliferative potential, and enhanced growth factor withdrawal-induced cell death. And, the effect of SHP-2 overexpression on growth factor-dependent survival was diminished in STAT5-deficient hematopoietic cells. Taken together, these results suggest that SHP-2 tyrosine phosphatase negatively regulates hematopoietic cell survival by dephosphorylation of STAT5.
Introduction
Growth factor-induced intracellular signaling pathways play an important role in maintaining homeostasis of the hematopoietic system (Dragovich et al., 1998; Wickremasinghe and Hoffbrand, 1999) . Committed hematopoietic progenitor cells require growth/survival factors such as interleukin (IL)-3 for both growth and survival; depletion of these trophic factors leads to programmed cell death (apoptosis). Since extracellular factors function through intracellular signal transduction, growth/survival factor-dependent signaling cascades such as the PI3K/Akt, Erk, and signal transducer and activator of transcription (STAT) pathways play important roles in determining hematopoietic cell survival or death. Accumulating evidence has demonstrated that dys-regulation of intracellular signal transduction induced by extracellular survival factors results in abnormal hematopoietic homeostasis, which may eventually lead to a variety of blood disorders including leukemia.
Recent studies have shown that growth/survival factor induced signaling events are functionally linked to the Bcl-2 family proteins that directly govern cell survival or death through apoptosis. For example, growth factor activated Akt kinase phosphorylates Bad (Datta et al., 1997; del Peso et al., 1997) , a proapoptotic member of the Bcl-2 family. The phosphorylated form of Bad associates with 14-3-3 adaptor protein (Zha et al., 1996) which in turn sequesters Bad away from Bcl-X L (an antiapoptotic protein), thus freeing Bcl-X L to exert its antiapoptotic effect. Another connection between growth factor signaling cascades and the apoptotic machinery is that growth factors promote hematopoietic cell survival by upregulation of Bcl-X L and pim-1 through activation of STAT5 (Dumon et al., 1999; Nosaka et al., 1999; Silva et al., 1999; Socolovsky et al., 1999) .
STAT5 is one of the six mammalian members of the STAT family that have been characterized. Both STAT5a and STAT5b isoforms are tyrosine phosphorylated and activated by a wide range of cytokines and hormones such as IL-3, GM-CSF, IL-2, erythropoietin, thrombopoietin, prolactin, and growth hormone (Rane and Reddy, 2002) . Activated STAT5 forms homo-or heterodimers, enters the nucleus, and binds to the specific DNA sequences in the promoter regions of various responsive genes, resulting in gene activation or repression. STAT5 has been shown to promote the IL-3 and IL-2 dependent survival of hematopoietic and lymphoid cells, respectively (Zamorano et al., 1998; Dumon et al., 1999) . Recent studies have revealed that STAT5 promotes hematopoietic cell survival by regulating the expression of a number of antiapoptotic proteins such as Bcl-X L (Dumon et al., 1999; Socolovsky et al., 1999; Shinjyo et al., 2001 ) and pim-1 (Nosaka et al., 1999) , and that tyrosyl phosphorylation of STAT5 is critical for this biological activity. STAT5 is phosphorylated and activated by Jak family kinases, particularly Jak2; however, it is not fully understood how this transcription factor is inactivated. Previous reports have suggested that STAT5 might be dephosphorylated by tyrosine phosphatases PTP1B and SHP-2 in the prolactin, IL-2, and erythropoietin signaling pathways (Aoki and Matsuda, 2000; Yu et al., 2000; Chughtai et al., 2002; Chen et al., 2003) , but the biological significance of their functional interactions remains uncharacterized.
SHP-2, an SH2 domain-containing protein tyrosine phosphatase, is ubiquitously expressed in a variety of tissues and cell types, and has been implicated in diverse signaling pathways, including those initiated by growth factors, cytokines, insulin, and interferons (Tonks and Neel, 2001; Qu, 2002) . A large body of evidence has demonstrated that, in most circumstances, SHP-2 plays a positive role in transducing the signal elicited from receptor tyrosine kinases such as EGF and FGF receptors (Tang et al., 1995; Bennett et al., 1996; Hadari et al., 1998; Shi et al., 1998) . This phosphatase is also highly expressed in hematopoietic cells and has been indicated to be involved in signal transduction of a number of hematopoietic growth factors, including IL-3 (Welham et al., 1994; Bone et al., 1997; Gu et al., 1998; . SHP-2 plays an essential role in the onset of hematopoietic development. We previously mutated the SHP-2 gene in mouse embryonic stem (ES) cells. Analyses of in vitro (Qu et al., 1997) and in vivo 
ES cells demonstrated that SHP-2 was required for primitive hematopoiesis. These results stand in contrast to the negative role of the closely related SHP-1 phosphatase in hematopoietic cell signaling. Indeed, our subsequent genetic analyses of hematopoietic development in the SHP-2/SHP-1 double mutant embryos confirmed opposing roles for SHP-2 and SHP-1 in regulating hematopoietic-lineage determination (Qu et al., 2001) .
Most recently, several gain-of-function mutations of SHP-2 have been identified in human juvenile myelomonocytic leukemia, myelodysplastic syndromes, and acute myeloid leukemia (Tartaglia et al., 2003) . These findings highlight the importance of studies on the function of SHP-2 in hematopoietic cells. Unfortunately, the detailed biochemical activities of SHP-2 phosphatase in the regulation of hematopoietic cell processes are not fully appreciated. We previously reported that SHP-2 played a positive role in IL-3-induced activation of Jak2 and Erk kinases in a catalytic-dependent manner . In the course of that work, we noticed that overexpression of WT SHP-2 in hematopoietic cells compromised their hematopoietic activities and enhanced their responses to growth factor deprivation-induced apoptosis. We have therefore further characterized the biological and biochemical activities of SHP-2 in the regulation of hematopoietic cell survival.
Results
Overexpression of SHP-2 increases the susceptibility of hematopoietic cells to growth factor withdrawal-induced death
In the course of our previous studies focusing on the role of tyrosine phosphatase SHP-2 in IL-3-induced signaling and cellular responses , we observed that Ba/F3 cells overexpressing catalytically inactive SHP-2 (SHP-2 C/S) were more susceptible to cell death. Following IL-3 withdrawal, cell survival rates of SHP-2 C/S clones were decreased compared to that of GFP control cells (Figure 1a ). Consistent with this observation, activation of caspase 3, an executioner protease in cellular apoptosis was increased in these cells (Figure 1b ). Since IL-3 is required for Ba/F3 cell survival and growth, the increased apoptosis appears to be attributed to the decrease in IL-3 signaling in these cells. We previously showed that IL-3-induced Jak2 kinase activation was significantly decreased in SHP-2 C/S cells . In agreement with that observation, activation (tyrosyl phosphorylation) of its downstream substrate STAT5 was attenuated (Figure 2) . Intriguingly, overexpression of WT SHP-2 in Ba/F3 cells also resulted in accelerated cell death following IL-3 starvation, and this effect was even greater than that seen in the C/S expressing cells (Figure 1a and c). The percentage of hypodiploid cells with sub-G1 DNA content, known to be apoptotic, was dramatically increased in WT SHP-2 overexpressing cells following starvation ( Figure 1c) . These results indicate that in addition to the regulatory role in hematopoietic cell proliferation and differentiation, SHP-2 phosphatase might also be involved in the regulation of hematopoietic cell survival/death.
Overexpression of WT SHP-2 phosphatase decreases tyrosyl phosphorylation of STAT5 while activation of Jak2 kinase is increased
To elucidate the underlying mechanisms by which SHP-2 modulates hematopoietic cell survival, we focused on IL-3 addition and deprivation-induced biochemical processes in WT SHP-2 overexpressing cells. As shown in Figure 3a , in response to IL-3 stimulation, activation of Jak2 kinase, defined by its tyrosyl phosphorylation, was significantly increased by overexpression of WT SHP-2. This result is consistent with our previous finding that SHP-2 plays a positive role in IL-3-induced Jak2 activation in a catalytic-dependent manner . Unexpectedly, activation of STAT5, a downstream target of Jak2 kinase, was found to be decreased rather than proportionally increased (Figure 3a) . Multiple experiments were conducted with several independent clones, producing similar results. In contrast, IL-3 activation of Akt and Erk kinases was slightly enhanced in WT SHP-2 overexpressing cells (Figure 3b ). Since Akt and Erk kinases promote cell survival (Datta et al., 1997; del Peso et al., 1997; Songyang et al., 1997) , this data indicates that the increased apoptosis of the cells overexpressing WT SHP-2 is not related to the PI3 kinase or Erk pathways.
SHP-2 phosphatase associates with and dephosphorylates STAT5
The observation that tyrosyl phosphorylation of STAT5 is decreased while Jak2 activation is increased in WT SHP-2 overexpressing cells raises the possibility that SHP-2 might directly inactivate STAT5. To test this possibility, we examined tyrosyl phosphorylation of STAT5 following IL-3 starvation. As illustrated in Figure 4a , after IL-3 withdrawal from the cell culture medium, the decay of STAT5 phosphorylation in Ba/F3 cells overexpressing WT SHP-2 was significantly WT SHP-2 transduced stable cell lines were selected by limiting dilution and anti-SHP-2 immunoblotting. Control (GFP positive whole-cell population sorted from the empty vector transduced cells), two independent WT SHP-2, and twao independent SHP-2 C/S clones previously generated were used for the experiments. (a) Exponentially growing cells were starved of IL-3 for the indicated periods of time. Cell survival rates were determined by the MTS assay . Expression of SHP-2 or SHP-2 C/S in individual clones is shown on the lower panel. (b) Caspase-3 activities of the cells were determined using the Caspase-3 Assay Kit according to the manufacturer's instructions 48 h following IL-3 starvation. (c) Exponentially growing cells were starved for 48 h. Cells were then harvested and fixed with 70% ethanol. Fixed cells were treated with RNase A (20 mg/ml) at 371C for 30 min, washed with PBS, and then stained with propidium iodide (50 mg/ml in PBS). Cellular DNA content was monitored using BD-LSR flowcytometry (BD Biosciences). The percentage of cells with sub-G1 DNA content (M1) was determined using the CELLQuestt software (BD Biosciences) (Yuan et al., 2003) . Two to four independent experiments were performed and similar results were obtained in each.
Results shown in (a) and (b) are the mean7s.d. of triplicates from one experiment SHP-2 phosphatase and hematopoietic cell survival J Chen et al accelerated relative to GFP control cells. Tyrosyl phosphorylation of STAT5 was barely detected 1 h after starvation vs 5 h in control cells. This phenotypic change appears to be specific to STAT5 as Jak2 kinase activity diminished comparably in both cell types. Since STAT5 regulates cellular survival by upregulation of antiapoptotic protein Bcl-X L (Dumon et al., 1999; Nosaka et al., 1999; Silva et al., 1999; Socolovsky et al., 1999) and pim-1 (Nosaka et al., 1999) , the expression of Bcl-X L and pim-1 was examined next. Consistent with the STAT5 phosphorylation response, following IL-3 deprivation, reduction of Bcl-X L and pim-1 expression in WT SHP-2 overexpressing cells was accelerated (Figure 4b ). Together these results imply that SHP-2 modulates IL-3-induced hematopoietic cell survival by dephosphorylating STAT5.
To better define the molecular mechanism by which SHP-2 phosphatase regulates STAT5 activity, we examined their physical and functional interactions. Consistent with previous reports (Yu et al., 2000; Chughtai et al., 2002; Chen et al., 2003) , anti-STAT5 immunoprecipitation followed by anti-SHP-2 immunoblotting showed that SHP-2 constitutively associated with STAT5 independent of IL-3 stimulation in SHP-2 overexpressing cells (data not shown). Further in vitro GST pull down assay demonstrated that only the phosphatase fragment could pull down STAT5 (data not shown), suggesting that the SHP-2/STAT5 interaction is direct and that this association is mediated by the C-terminal part of SHP-2 but not the SH2 domains.
Since SHP-2 associates with STAT5, their functional interplay was next determined. Anti-STAT5 immunoprecipitates prepared from IL-3 stimulated parental Ba/ F3 cells were incubated in tyrosine phosphatase assay buffer for various periods of time and the phosphorylation status of STAT5 in the immunoprecipitates was examined. As expected, tyrosyl phosphorylation of STAT5 decreased along with the incubation time, and the dephosphorylation could be blocked by a tyrosine phosphatase inhibitor, orthovanadate (Figure 4c ). Since SHP-2 physically interacts with STAT5, this result indicates that the SHP-2 existing in the anti-STAT5 immunocomplex dephosphorylates STAT5. To further examine the phosphatase activity of SHP-2 on STAT5, we incubated anti-STAT5 immunoprecipitates with purified GST-SHP-2 fusion protein and analyzed tyrosyl phosphorylation of STAT5. GST-SHP-2 but not GST-SHP-2 SH2 domains dephosphorylated STAT5 and this function was clearly dose-dependent. In all, 10 mg GST-SHP-2 completely dephosphorylated STAT5 (Figure 4d ). Taken together, these results further confirm that SHP-2 interacts with STAT5 both physically and functionally.
Stat5 plays an important role in hematopoietic cell survival
The above results showed that STAT5 activity was reduced in SHP-2 overexpressing cells, to determine whether the decreased STAT5 activity was connected to Exponentially growing Ba/F3 clones, GFP control and two independent WT SHP-2 overexpressing, were starved for 5 h and then stimulated with IL-3 for 30 min. The cells were washed and seeded into IL-3-free medium for the indicated periods of time before being harvested for the following analyses. (a) Tyrosyl phosphorylation of STAT5a and Jak2 kinase was examined as described in Figure 3 . (b) Cell lysates prepared from the cells cultured in IL-3-free medium for 24 h were examined for Bcl-X L and pim-1 expression. (c) AntiSTAT5b immunoprecipitates prepared from IL-3 stimulated GFP control cells as described above were incubated in phosphatase assay buffer with or without addition of sodium orthovanadate (1 mM) for the indicated periods of time. Tyrosine phosphorylation of STAT5 was then analysed by anti-PY immunoblotting. (d) Anti-STAT5b immunoprecipitates were incubated with GST-SHP-2 (full length) or GST-SHP-2 SH2 domains (amino acids 1-243 including two SH2 domains) GST fusion proteins at various concentrations in phosphatase assay buffer for 30 min. Tyrosyl phosphorylation of STAT5 was then examined. 'C' indicates the nonincubated control. Blots were stripped and reprobed with anti-Jak2, anti-STAT5a, anti-tubulin, and anti-STAT5b Abs, respectively, to examine protein loading. Representative results from two independent experiments are shown SHP-2 phosphatase and hematopoietic cell survival J Chen et al the enhanced hematopoietic cell apoptosis, we next examined the role of STAT5 in hematopoietic cell survival. Bone marrow-derived macrophages (BMDM) were generated from WT and STAT5-deficient mice as we previously reported (Yu et al., 2002) . They were maintained in IL-3-containing medium for 2 days and cell survival rates following IL-3 deprivation were then assessed. As shown in Figure 5a , STAT5 À/À cells showed increased cell death compared to WT control cells, and expression level of Bcl-X L was barely detectable in STAT5 À/À cells following 24 h of starvation, consistent with the essential role for STAT5 in maintaining erythroid progenitor and mast cell survival and the observation that Bcl-X L was not detected in growth factor-starved STAT5 À/À mast cells (Socolovsky et al., 1999; Shelburne et al., 2003) . To further confirm the role of STAT5 in hematopoietic cell survival, we transduced Ba/F3 cells with a dominant-negative STAT5 mutant (STAT5aD757) (the C-terminal transactivation domain is deleted) (Wang et al., 2000; Shelburne et al., 2003) . Transduced cells were sorted and assayed for survival after IL-3 withdrawal. In agreement with the results obtained from STAT5-deficient BMDMs, interference of endogenous STAT5 function by a dominant-negative mutant STAT5 also enhanced growth factor withdrawal-induced Ba/F3 cell death (Figure 5b) . Reduction of pim-1 expression induced by starvation was enhanced in the dominant-negative STAT5 overexpressing cells. These results together confirm an important role for the STAT5/Bcl-X L , pim-1 pathway in hematopoietic cell survival. In addition, we examined colony-forming potential of STAT5-deficient bone marrow progenitor cells in IL-3-containing methylcellulose and liquid medium. The results also support that STAT5 activity is required for optimal response to IL-3, an effect that was most evident at low doses of the cytokine (data not shown). Hematopoietic cell sensitivity to growth factor withdrawal-induced apoptosis is increased by loss of STAT5 function. (a) BMDM were generated from WT and STAT5-deficient mice as we previously reported (Yu et al., 2002) . They were maintained in IL-3-containing medium (20 ng/ml) for 2 days and cell survival rates were then assessed 24 and 48 h following IL-3 withdrawal. Expression of Bcl-X L was examined 24 h after starvation. (b) Ba/F3 cells were transduced with dominant-negative STAT5aD757. Transduced cells were sorted and subjected to the cell survival assay at the indicated time points after IL-3 deprivation. The expression level of pim-1 was examined 24 h after IL-3 starvation. 'C' and 'S' indicate control and starved cells, respectively. The blots were stripped and reprobed with anti-STAT5 Ab from BD Transduction Laboratories (that detects both STAT5a and STAT5b) and anti-tubulin Ab.
Results shown are a representative of two independent experiments SHP-2 phosphatase and hematopoietic cell survival J Chen et al overexpression of SHP-2 on hematopoietic progenitor cell function. Primary bone marrow cells were transduced with WT SHP-2 by retroviral-mediated gene transfer. Transduced cells were sorted based on GFP expression and then assayed for colony formation in methylcellulose medium containing a full combination of hematopoietic growth factors (see Materials and methods) or IL-3 alone. As shown in Figure 6a , overexpression of SHP-2 attenuates colony-forming capacities of the progenitor cells. In agreement with this result, the expansion rate of progenitor cells overexpressing SHP-2 in IL-3-containing liquid culture was also reduced (Figure 6b ). To test whether the above phenotypic changes of the SHP-2 transduced cells resulted from enhanced apoptosis, we transduced WT bone marrow cells with SHP-2 and the vector. Cells (unsorted) were maintained in growth factor containing medium for 48 h. Percentages of gene transduced cells (GFP positive) in these mixed cell populations were then determined by FACS before and 48 h after growth factor starvation. As shown in Figure 7a , after 2 days of starvation, the percentage of SHP-2 transduced cells dropped much faster than that of the GFP vector transduced cells, suggesting that WT SHP-2 overexpressing cells died much faster than nontransduced cells.
Furthermore, we transduced WT and STAT5-deficient bone marrow progenitor cells with SHP-2 phosphatase and the GFP vector control. Transduced cells were sorted and maintained in IL-3-containing medium for 2 days and then assayed for survival following IL-3 withdrawal. Consistent with the results shown in Figure 6 , overexpression of SHP-2 phosphatase in WT primary hematopoietic cells decreased cell survival, suggesting that excessive SHP-2 enzyme sensitized hematopoietic cells to growth factor deprivation-induced death. Interestingly, the effect of SHP-2 overexpression on cell survival in STAT5-deficient hematopoietic cells was diminished (Figure 7b ), indicating an important role for STAT5 in the SHP-2 regulation of hematopoietic cell survival.
Discussion
In this report we have provided evidence that SHP-2 tyrosine phosphatase negatively regulates hematopoietic cell survival. Enforced expression of SHP-2 in bone marrow progenitor cells compromised their hematopoietic potential and enhanced their susceptibility to apoptosis following growth factor deprivation. Biochemical analyses suggest that SHP-2 modulates hematopoietic cell survival by interaction with STAT5. We have shown that SHP-2 associates with and dephosphorylates STAT5. Although IL-3 activation of Jak2 kinase was increased by overexpression of WT SHP-2, tyrosyl phosphorylation of the Jak2 downstream substrate, STAT5, was disproportionately decreased. Following IL-3 starvation, tyrosyl phosphorylation of STAT5 required for its antiapoptotic activity was rapidly diminished in SHP-2 overexpressing cells. These results suggest that, in addition to its role in hematopoietic cell proliferation and differentiation, SHP-2 is also involved in regulation of hematopoietic cell survival, thereby providing new insights into the biological function of SHP-2 phosphatase in hematopoietic cell processes. SHP-2 appears to play compound roles in hematopoietic cell processes. Although SHP-2 targeted deletion mutation severely suppresses hematopoietic development (Qu et al., 1997 , this might be mainly due to loss of its promoting role in early differentiation process of ES cells Chan et al., 2003) . Therefore, it has been unclear how SHP-2 phosphatase is exactly involved in hematopoietic stem/progenitor cell processes. Since SHP-2 knockout embryos do not survive past midgestation (Qu et al., 1997; Saxton et al., 1997) , the number of SHP-2 mutant hematopoietic cells available is extremely limited. Dominant-negative inhibition and overexpression approaches are very useful for addressing certain aspects of SHP-2 function in the hematopoietic compartment. We have been investigating the role of SHP-2 phosphatase in IL-3-mediated hematopoietic cell responses. By using a dominantnegative approach, we previously reported that SHP-2 functioned in both enzymatic activity-dependent andindependent manners in IL-3-induced signaling and cellular responses . Complete removal of SHP-2 protein results in loss of all its functions, so IL-3 signal transduction in SHP-2-deficient cells was essentially blocked. However, in catalytically inactive SHP-2 overexpressing Ba/F3 cells, only the IL-3-induced Jak/STAT and Erk pathways were attenuated. Due to the important role in Jak2 and Erk activation, SHP-2 catalytic activity is required for optimal hematopoietic cell responses to IL-3-induced proliferation and differentiation (Wheadon et al., 2003; .
By using an overexpression approach, we now provide evidence that SHP-2 also modulates growth factor-dependent hematopoietic cell survival. Biological and biochemical data in this report showed that in spite of the positive role of SHP-2 in IL-3 activation of Jak2 and Erk kinases, enforced expression of WT SHP-2 increased Ba/F3 cell susceptibility to IL-3 depletioninduced apoptosis. Moreover, overexpression of SHP-2 in primary hematopoietic progenitor cells in fact compromised their hematopoietic potential both in vitro (Figure 6 and 7) and in vivo (Chen and Qu, unpublished data) . Recently, several gain-of-function mutations of SHP-2 have been identified in human juvenile myelomonocytic leukemia, myelodysplastic syndromes, and acute myeloid leukemia (Tartaglia et al., 2003) . These findings would indicate that excessive SHP-2 phosphatase might contribute to hematopoietic cell transformation. However, our studies in this report clearly suggest that this is not likely to be the case, thus raising an interesting question on how the gain-of-function mutations of SHP-2 contribute to hematopoietic cell transformation. It is likely that in addition to the increased catalytic activities, the gain-of-function SHP-2 mutants also have altered protein-protein interacting properties and that these changes together contribute to leukemogenesis. Certainly, further studies are needed to determine how these mutants disturb hematopoietic cell signaling and cellular processes.
SHP-2 appears to modulate hematopoietic cell survival by dephosphorylation of STAT5 One interesting observation in this report is that while IL-3-induced activation of Jak2 kinase was increased by overexpression of SHP-2, tyrosyl phosphorylation of the Jak2 substrate-STAT5 was decreased (Figure 3a) , and that following IL-3 withdrawal, the decay of STAT5 phosphorylation in SHP-2 overexpressing cells was dramatically accelerated (Figure 4a ). These results, together with subsequent physical association analysis and the in vitro dephosphorylation assay (Figure 4c and  d) , strongly support the functional interplay between SHP-2 and STAT5. It is important to point out that although SHP-2 inactivates STAT5, the net tyrosine phosphorylation status of STAT5 in the catalytically inactive SHP-2 (SHP-2 C/S) cells was not increased, but instead was decreased (Figure 2) , this is because activation of upstream Jak2 kinase in SHP-2 C/S overexpressing cells was significantly decreased by the interference of the catalytic activity of endogenous SHP-2 .
The interaction between SHP-2 and STAT5, in particular, the physiological significance of their functional interplay has not been well characterized. The association between SHP-2 and STAT5 was first reported in the IL-2-induced signal transduction (Yu et al., 2000) . Following that, SHP-2 and STAT5 were found to be in the same immunocomplex in mouse mammary HC11 and human breast cancer T47D cells and to translocate into the nucleus upon stimulation by prolactin (Chughtai et al., 2002) . More recently, SHP-2 was shown to dephosphorylate STAT5a in mouse fibroblast cells (Chen et al., 2003) . However, the physiological significance of their interaction, particularly, in hematopoietic cell processes, has not been defined. Our studies have now demonstrated that SHP-2 associates with STAT5 and that this interaction negatively regulates IL-3-induced cell survival and hematopoietic activity.
It appears that enhanced dephosphorylation of STAT5 by excessive SHP-2 accounts for increased cell death. This notion is supported by the following evidence. First, STAT5 plays an important role in hematopoietic cell survival. Following growth factor withdrawal, STAT5-deficient primary hematopoietic cells and dominant-negative STAT5 overexpressing Ba/F3 cells are more susceptible to undergo apoptosis than WT or the vector control transduced counterparts ( Figure 5 ). Moreover, STAT5-deficient bone marrow hematopoietic cells showed decreased hematopoietic potential in sub-optimal IL-3-containing medium (data now shown). Second, starvation-induced reduction of the expression levels of antiapoptotic proteins Bcl-X L and pim-1, two STAT5 downstream targets, was enhanced by overexpression of SHP-2 phosphatase. Third, overexpression of SHP-2 decreases cell survival only in WT but not in STAT5-deficient hematopoietic cells. No significant difference in cell survival was observed between SHP-2 overexpressing and the vector transduced STAT5
À/À cells (Figure 7b ), suggesting that the negative regulation of growth factor-dependent hematopoietic cell survival by SHP-2 is mediated by STAT5. However, since STAT5 plays an important role in hematopoietic cell survival (Figure 5 ), it remains possible that diminished SHP-2 effect in STAT5 À/À hematopoietic cells might be attributed to lack of STAT5 activation of downstream antiapoptotic molecules. Certainly, further experiments are required to address this concern.
Materials and methods

Mice, cell lines, and reagents
STAT5a/b
þ /À mice and dominant-negative STAT5aD757 were generously provided by Dr James Ihle (Memphis, TN, USA). The mouse colony was maintained at the American Red Cross Vivarium. STAT5ab À/À mice were produced and genotyped as previously reported (Teglund et al., 1998; Bunting et al., 2002) . Ba/F3, a murine pro-B lymphoma cell line was routinely maintained in RPMI-1640 medium with 10% fetal bovine serum (FBS) and 10% conditioned medium produced by murine IL-3 cDNA transfected XB-30 hematopoietic cells. Anti-SHP-2, anti-STAT5a, anti-STAT5b, anti-Bcl-X L , antiErk, and anti-phospho-Erk antibodies (Abs) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-STAT5 Ab that detects both STAT5a and STAT5b was supplied by BD Transduction Laboratories (San Diego, CA, USA). Anti-phospho-tyrosine Ab (PY) (4G10) and Jak2 antiserum were obtained from Upstate Biotechnology Inc. (Lake Placid, NY, USA). Anti-phospho-Akt and anti-Akt Abs were purchased from Cell Signaling Technology (Beverly, MA, USA). The Cellular Caspase-3 Activity Assay Kit was supplied by Calbiochem (La Jolla, CA, USA).
